#### Rule 3.19A.2

# **Appendix 3Y**

## **Change of Director's Interest Notice**

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	4DMedical Limited
ABN	31 161 684 831

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Julian Bernard Kingsley Sutton
Date of last notice	14 August 2020

#### Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct and indirect	
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Vinegar Hill Partners Pty Ltd (an entity controlled by Julian Sutton)	
Date of change	21 November 2024	
No. of securities held prior to change	Direct:   297,786 ordinary shares   4,266,666 unquoted options with exercise   price of \$1.20 and expiry date of 15 March   2027   910,150 unquoted options with exercise   price of \$0.40 and expiry date of 1 March   2025   1,028,346 unquoted options with exercise   price of \$0.40 and expiry date of 1 March   2025   Indirect:   183,014 ordinary shares	
Class	Options	

<sup>+</sup> See chapter 19 for defined terms.

Number acquired	60,147
Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Options issued as a component of director's remuneration (valued at \$36,250 based on the 30-day-VWAP of \$0.6027 as at 1 July 2024).
No. of securities held after change	Direct: 297,786 ordinary shares 4,266,666 unquoted options with exercise price of \$1.20 and expiry date of 15 March 2027 910,150 unquoted options with exercise price of \$0.40 and expiry date of 1 March 2025 1,028,346 unquoted options with exercise price of \$0.40 and expiry date of 1 March 2025 60,147 unquoted options with a nil exercise price and expiry date of 30 June 2029 Indirect: 183,014 ordinary shares
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy- back	Issue of options as approved at Annual General Meeting on 20 November 2024.

### Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A

<sup>+</sup> See chapter 19 for defined terms.

Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

### Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a <sup>+</sup> closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

<sup>+</sup> See chapter 19 for defined terms.